Docality.com Logo
 
Dr. Omar  Kazi  Md image

Dr. Omar Kazi Md

1045 N Courtenay Pkwy
Merritt Island FL 32953
321 533-3937
Medical School: Hahnemann University College Of Medicine - 1996
Accepts Medicare: Yes
Participates In eRX: Yes
Participates In PQRS: Yes
Participates In EHR: Yes
License #: ME81029
NPI: 1831134071
Taxonomy Codes:
207W00000X

Request Appointment Information

Awards & Recognitions

About Us

Practice Philosophy

Conditions

Dr. Omar Kazi is associated with these group practices

Procedure Pricing

HCPCS Code Description Average Price Average Price
Allowed By Medicare
HCPCS Code:66821 Description:After cataract laser surgery Average Price:$596.60 Average Price Allowed
By Medicare:
$309.01
HCPCS Code:66821 Description:After cataract laser surgery Average Price:$600.00 Average Price Allowed
By Medicare:
$326.62
HCPCS Code:67820 Description:Revise eyelashes Average Price:$100.00 Average Price Allowed
By Medicare:
$49.71
HCPCS Code:92083 Description:Visual field examination(s) Average Price:$125.00 Average Price Allowed
By Medicare:
$87.12
HCPCS Code:92133 Description:Cmptr ophth img optic nerve Average Price:$81.40 Average Price Allowed
By Medicare:
$44.38
HCPCS Code:92134 Description:Cptr ophth dx img post segmt Average Price:$81.03 Average Price Allowed
By Medicare:
$44.38
HCPCS Code:92225 Description:Special eye exam initial Average Price:$60.00 Average Price Allowed
By Medicare:
$26.12
HCPCS Code:92012 Description:Eye exam established pat Average Price:$107.08 Average Price Allowed
By Medicare:
$81.61
HCPCS Code:92250 Description:Eye exam with photos Average Price:$82.88 Average Price Allowed
By Medicare:
$66.77
HCPCS Code:99214 Description:Office/outpatient visit est Average Price:$119.50 Average Price Allowed
By Medicare:
$103.41
HCPCS Code:99204 Description:Office/outpatient visit new Average Price:$174.05 Average Price Allowed
By Medicare:
$160.73
HCPCS Code:92004 Description:Eye exam new patient Average Price:$155.45 Average Price Allowed
By Medicare:
$142.96
HCPCS Code:92014 Description:Eye exam & treatment Average Price:$130.08 Average Price Allowed
By Medicare:
$118.32
HCPCS Code:92226 Description:Special eye exam subsequent Average Price:$30.00 Average Price Allowed
By Medicare:
$23.06

HCPCS Code Definitions

92250
Fundus photography with interpretation and report
92226
Ophthalmoscopy, extended, with retinal drawing (eg, for retinal detachment, melanoma), with interpretation and report; subsequent
66821
Discission of secondary membranous cataract (opacified posterior lens capsule and/or anterior hyaloid); laser surgery (eg, YAG laser) (1 or more stages)
92225
Ophthalmoscopy, extended, with retinal drawing (eg, for retinal detachment, melanoma), with interpretation and report; initial
92134
Scanning computerized ophthalmic diagnostic imaging, posterior segment, with interpretation and report, unilateral or bilateral; retina
67820
Correction of trichiasis; epilation, by forceps only
92004
Ophthalmological services: medical examination and evaluation with initiation of diagnostic and treatment program; comprehensive, new patient, 1 or more visits
66821
Discission of secondary membranous cataract (opacified posterior lens capsule and/or anterior hyaloid); laser surgery (eg, YAG laser) (1 or more stages)
92012
Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient
92083
Visual field examination, unilateral or bilateral, with interpretation and report; extended examination (eg, Goldmann visual fields with at least 3 isopters plotted and static determination within the central 30°, or quantitative, automated threshold perimetry, Octopus program G-1, 32 or 42, Humphrey visual field analyzer full threshold programs 30-2, 24-2, or 30/60-2)
92014
Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; comprehensive, established patient, 1 or more visits
92133
Scanning computerized ophthalmic diagnostic imaging, posterior segment, with interpretation and report, unilateral or bilateral; optic nerve
99204
Office or other outpatient visit for the evaluation and management of a new patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 45 minutes are spent face-to-face with the patient and/or family.
99214
Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: A detailed history; A detailed examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 25 minutes are spent face-to-face with the patient and/or family.

Medical Malpractice Cases

None Found

Medical Board Sanctions

None Found

Referrals

NPI
Doctor Name
Specialty
Count
1669475646
Cardiovascular Disease (Cardiology)
521
1609871748
Pulmonary Disease
506
1386692804
Cardiovascular Disease (Cardiology)
456
1912009168
Internal Medicine
399
1245288505
Cardiovascular Disease (Cardiology)
396
1083657951
Diagnostic Radiology
317
1801892245
Pulmonary Disease
311
1306948344
Ophthalmology
275
1427057256
Endocrinology
261
1942225883
Cardiovascular Disease (Cardiology)
261
*These referrals represent the top 10 that Dr. Kazi has made to other doctors

Publications

A multicentered phase III comparative clinical trial of depot-medroxyprogesterone acetate given three-monthly at doses of 100 mg or 150 mg: II. The comparison of bleeding patterns. World Health Organization. Task Force on Long-Acting Systemic Agents for F - Contraception
A multicentered phase III clinical trial was conducted in seven countries to compare two dosages of depot-medroxyprogesterone acetate (DMPA), 100mg and 150mg, given every 90 days. Contraceptive efficacy and side-effects of both regimens were reported previously. Their effect on vaginal bleeding patterns is the object of this paper. A total of 1216 women were randomly assigned to a dose group and 1156 of them provided a menstrual diary. The comparison of the bleeding patterns is made using a 90-day reference period approach and following the guidelines published by WHO. In addition, the longest bleeding/spotting episode and the longest bleeding/spotting-free interval are calculated over the entire diary length. The only difference found between the two dose groups is a higher incidence of amenorrhea with the 150mg regimen. Overall, there is a high degree of consistency between the reasons given by individual women for discontinuing the contraceptive method and their vaginal bleeding pattern during the 90 days preceding discontinuation. However the data revealed large between-centre differences, both in the incidence of specific patterns, and in the identification by women of bleeding problems as reasons for discontinuation. This last point suggests that the life-table analysis underestimates the true incidence of menstrual irregularities. Comments on the reference period analysis method are made.
A multicentred phase III comparative clinical trial of depot-medroxyprogesterone acetate given three-monthly at doses of 100 mg or 150 mg: 1. Contraceptive efficacy and side effects. World Health Organization Task Force on Long-Acting Systemic Agents for - Contraception
Two dosages of depot-medroxyprogesterone acetate (DMPA), 100 mg and 150 mg given every 90 days, were compared in two groups of women with regard to effectiveness, reported complaints and reasons for discontinuation. A total of 1216 women were recruited into a seven-centre, multinational, randomized clinical trial. Follow-up was for a period of one year and resulted in a total of 5507 woman-months of experience of 100 mg DMPA and 5429 woman-months of experience of the 150 mg dose. The study showed little difference in efficacy and side effects between the two treatment groups. Two pregnancies occurred in women receiving 100 mg DMPA giving a Pearl Index of 0.44 per 100 woman-years. None occurred in the 150 mg group. There was no difference in the overall continuation rates between the two groups at one year, being 59.3% in the 100 mg group and 58.8% in the 150 mg group. Except for discontinuation of method use for amenorrhea, the rates of all medical and non-medical reasons given for discontinuation were comparable between the two treatment groups. Women's perception of lack of bleeding was reported as amenorrhea and resulted in discontinuation rates at 12 months for amenorrhea of 7.2% for women receiving 100 mg of DMPA and 12.5% for those receiving the 150 mg dose. Three centres, Alexandria, Karachi and Szeged, made the major contributions to this difference.

Map & Directions

1045 N Courtenay Pkwy Merritt Island, FL 32953
View Directions In Google Maps

Nearby Doctors

255 Borman Dr 2Nd Floor
Merritt Island, FL 32953
321 341-1640
2404 N Courtenay Pkwy Suite D
Merritt Island, FL 32953
321 524-4470
2404 N Courtenay Pkwy
Merritt Island, FL 32953
321 521-1327
825 N Courtenay Pkwy
Merritt Island, FL 32953
321 522-2563
2180 N Courtenay Pkwy
Merritt Island, FL 32953
321 523-3388
255 Borman Dr
Merritt Island, FL 32953
321 341-1640
1395 N Courtenay Pkwy Suite # 200
Merritt Island, FL 32953
321 591-1333
Brevard County Health Department 2575 N Courtenay Pkwy
Merritt Island, FL 32953
321 547-7148
210 N Grove Street
Merritt Island, FL 32953
321 527-7878
595 N Courtenay Pkwy Suite 101
Merritt Island, FL 32953
321 848-8211